ALSO NOTED: Gilead drug beats out competition; Solvay gets approvable letter; Galenica beats forecasts

> A new research report concludes that Gilead may be stealing GlaxoSmithKline's "Best anti-HIV drug maker" crown, thanks to Gilead's drug-combo pill Atripla. The study found that Atripla was the HIV drug most requested by patients, and that doctors rated Gilead's drugs just a bit higher than GlaxoSmithKline's. Release

> Solvay Pharmaceuticals got an approvable letter for its pancreatic enzyme Creon, used to treat problems related to cystic fibrosis and chronic pancreatitis. The FDA is asking for additional clinical data and manufacturing information before final approval, but the company says, of course, that it's confident it can provide the data. Release

> Swiss drug maker and healthcare products supplier Galenica posted forecast-beating first-half profits of $57.3 million, sending its shares up 4 percent. Report

> Enzon Pharmaceuticals is raising some cash with the sale of a quarter interest in its royalties from Peg-Intron, its hepatitis C treatment marketed by Schering-Plough. Part of the sale proceeds will go to retire debts coming due next year. Release

And Finally... More seniors may have prescription drug coverage because of Medicare Part D, but that doesn't mean more seniors are getting all their drugs. Article  

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.